Summary
The elimination of pindolol was studied in 32 patients suffering from various liver diseases, mainly acute hepatitis and hepatic cirrhosis. The total body clearance of antipyrine was measured simultaneously as a parameter of liver microsomal enzyme activity. The doses given were antipyrine 1000 mg orally and pindolol 3 mg i.v. Plasma samples were taken and urine was collected for up to 72 h for the measurement of drug concentrations. In addition, conventional biochemical laboratory tests were done. The total body clearance of antipyrine was compared with the pharmacokinetic parameters calculated for pindolol, and the results of the biochemical tests. No correlation was found between antipyrine clearance and the routine biochemical parameters in liver disease or with the total body clearance of pindolol. A significant correlation was seen with the nonrenal clearance of pindolol taken as representing its major metabolic degradation. Higher correlation coefficients were observed when two subgroups of patients with acute hepatitis and hepatic cirrhosis were separated. In some patients suffering from hepatic cirrhosis a higher urinary excretion of unchanged pindolol was observed as liver function become decompensated, a finding due to an unknown mechanism but based on intact renal function. In patients with acute hepatitis a much higher nonrenal clearance was found than in many other patients, which might be based on increased liver blood flow.
Similar content being viewed by others
References
Andreasen PB, Ranek L, Statland BE, Tygstrup N (1974) Clearance of antipyrine-dependence of quantitative liver function. Eur J Clin Invest 4: 129–134
Andreasen PB, Greisen G (1976) Phenazone metabolism in patients with liver disease. Eur J Clin Invest 6: 21–26
Black M (1974) Liver disease and drug therapy. Med Clin North Am 58: 1051–1057
Branch RA, Herbert CM, Read AE (1973) Determinants of serum antipyrine half-lives in patients with liver disease. Gut 14: 569–573
Brodie BB, Axelrod J, Soberman R, Levy BB (1949) The estimation of antipyrine in biological materials. J Biol Chem 179: 25–29
Brodie BB, Axelrod J (1950) The fate of antipyrine in man. J Pharmacol Exp Ther 98: 97–104
Gugler R, Herold W, Dengler HJ (1974) Pharmacokinetics of pindolol in man. Eur J Clin Pharmacol 7: 17–24
Gugler R, Bodem G (1978) Single and multiple dose pharmacokinetics of pindolol. Eur J Clin Pharmacol 13: 13–16
Hvidberg EF, Andreasen PB, Ranke L (1974) Plasma half-life of phenylbutazone in patients with impaired liver function. Clin Pharmacol Ther 15: 171–177
Klotz U, Fischer C, Müller-Seydlitz P, Schulz J, Müller WA (1979) Alterations in the disposition of differently cleared drugs in patients with cirrhosis. Clin Pharmacol Ther 26: 221–227
Lundbergh P, Strandell T (1974) Changes in hepatic circulation at rest, during and after exercise in young males with infectious hepatitis compared with controls. Acta Med Scand 196: 315–325
Meier J, Nüesch E (1977) Pindolol, a beta-adrenoceptor blocking agent with a negligible first-pass effect. Br J Clin Pharmacol 4: 371–372
Meier J (1979) β-Adrenoceptor-blocking-agents: Pharmacokinetic differences and their clinical implications illustrated on pindolol. Cardiology 64: 1–13
Ohnhaus EE, Nüesch E, Meier J, Kalberer F (1974) Pharmacokinetics of unlabelled and14C-labelled pindolol in uraemia. Eur J Clin Pharmacol 7: 25–29
Ohnhaus EE, Martin J, Kinser J, Colombo JP (1977) Enzyme induction and renal function in man. Br J Clin Pharmacol 4: 33–37
Ohnhaus EE, Park BK (1979) Measurement of urinary 6-β-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur J Clin Pharmacol 15: 139–145
Pacha WL (1969) A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB 46), a β-blocking agent, in plasma and urine. Experientia (Basel) 25: 802–803
Preisig R, Rankin J, Sweeting J, Bradley SE (1966) Hepatic haemodynamics during viral hepatitis in man. Circulation 34: 188–197
Sachs L (1978) Angewandte Statistik. Springer, Berlin Heidelberg New York
Soberman R, Brodie BB, Levy BB, Axelrod J, Hollander V, Steele JM (1949) The use of antipyrine in the measurement of total body water in man. J Biol Chem 179: 31–42
Sotaniemi EA, Anttila M, Pelkonen OR, Järvensivu P, Sundquist A (1979) Plasma clearance of propranolol and sotalol and hepatic drug-metabolizing enzyme activity. Clin Pharmacol Ther 26: 153–161
Vesell ES, Passananti GT (1973) Inhibition of drug metabolism in man. Drug Metab Dispos 1: 402–410
Wilkinson GR, Schenker S (1976) Effects of liver disease on drug disposition in man. Biochem Pharmacol 25: 2675–2681
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ohnhaus, E.E., Münch, U. & Meier, J. Elimination of pindolol in liver disease. Eur J Clin Pharmacol 22, 247–251 (1982). https://doi.org/10.1007/BF00545223
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00545223